Shares of ImmuPharma plc (LON:IMM – Get Free Report) were down 14.7% during trading on Monday . The company traded as low as GBX 3.40 and last traded at GBX 3.40. Approximately 1,369,060 shares were traded during mid-day trading, a decline of 46% from the average daily volume of 2,540,783 shares. The stock had previously closed at GBX 3.99.
ImmuPharma Stock Performance
The company has a market cap of £22.15 million, a P/E ratio of -9.59 and a beta of 3.01. The business’s 50-day moving average price is GBX 3.97 and its 200 day moving average price is GBX 4.90.
ImmuPharma (LON:IMM – Get Free Report) last issued its earnings results on Wednesday, May 27th. The company reported GBX (0.37) earnings per share (EPS) for the quarter. ImmuPharma had a net margin of 3,519.56% and a negative return on equity of 353.21%. Equities research analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Pathward’s Credit Scare Tests Its Comeback Story
- Wiring the AI Boom: Rumble’s $13.7B Pivot
- StoneX: Too Far Too Fast?
- DICK’s Sporting Goods Faces Pain Now for a Bigger Prize
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
